| Product Disclosure Statement |
Updated information |
|---|
Important Update on Direct Life Insurance policies issued between 21 May 2016 and 31 May 2019
ANZ Life Insurance (21 May 2016)
ANZ Recover Well (21 May 2016)
ANZ Income Protection (21 May 2016)
|
This Significant Event Notice applies to ANZ Life Insurance, ANZ Recover Well and ANZ Income Protection policies issued by OnePath Life (and OnePath General for ANZ Income Protection). If your policy is directly impacted by these changes then you should have received your copy already.
If you require further information regarding these changes, please contact Customer Care on 132 062 for assistance.
|
ANZ Life Insurance dated 1 June 2019
|
The following information is to be read in conjunction with the ‘Critical Illness Cover (optional)’ section on page 16 of the PDS.
Life Insurance Code of Practice
We have adopted the Life Insurance Code of Practice, which contains minimum standard medical definitions for certain conditions. This means that where your critical illness cover includes one of the conditions defined under the Code and you make a claim, we will assess your claim against the better of the following definitions:
a) the applicable definition in the PDS for the covered condition
b) if different from a) above, the corresponding minimum standard medical definition in the Code that is current at the time of the insured event.
The minimum standard medical definitions provided under the Code only apply to critical illness cover where we issued your policy on or after 1 July 2017. They do not apply to any of the following:
a) other benefits such as critical illness cover either reinstated after a claim or where the amount payable varies according to the severity of the condition
b) to payments for benefits included with Income Protection or Total and Permanent Disability (TPD).
The minimum standard medical definitions provided under the Code are:
a) Cancer – excluding specified early-stage cancers
Cancer means any malignant tumour diagnosed with histological confirmation and characterised by:
a) the uncontrolled growth of malignant cells; and
b) invasion and destruction of normal tissue beyond the basement membrane.
The term malignant tumour includes leukaemia, sarcoma and lymphoma.
The following are not covered:
- All tumours which are histologically classified as any of the following:
a) pre-malignant;
b) non-invasive;
c) high-grade dysplasia;
d) borderline or low malignant potential.
- Carcinoma in situ except carcinoma in situ of the breast where a total mastectomy with full removal of the breast has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the prostate unless:
a) histologically classified as having a Gleason score of 7 or above; or
b) having progressed to at least clinical stage T2bN0M0 on the TNM clinical staging system; or
c) where a total prostatectomy has been undertaken where the procedure was specifically to arrest the spread of malignancy and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the thyroid unless:
a) having progressed to at least TNM classification T2N0M0; or
b) where a total thyroidectomy has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the bladder unless having progressed to at least TNM classification T1N0M0.
- Cutaneous lymphoma confined to the skin.
- Chronic lymphocytic leukaemia unless having progressed to at least Rai stage I.
- All non-melanoma skin cancers unless having spread to the bone, lymph node, or another distant organ.
- All melanoma skin cancers unless having progressed to at least TNM classification T2bN0M0.
b) Heart attack – with evidence of severe heart muscle damage
Heart attack means the death of a portion of the heart muscle as a result of inadequate blood supply, where the diagnosis is supported by the detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) and with at least three of the following:
a) Symptoms of ischaemia.
b) New significant ST-segment–T wave (ST–T) ECG changes or new left bundle branch block (LBBB).
c) Development of new pathological Q waves in the ECG.
d) Imaging evidence of new regional wall motion abnormality present at least six weeks after the event.
If the tests specified in a) to d) above are inconclusive or unable to be met, then the definition will be met if at least three months after the event the insured's left ventricular ejection fraction is less than 50 per cent.
The following are not covered:
- A rise in biological markers as a result of an elective percutaneous procedure for coronary artery disease.
- Other acute coronary syndromes including but not limited to angina pectoris.
c) Stroke – in the brain resulting in specified permanent impairment
Stroke means death of brain tissue caused by one of the following:
a) Ischaemic infarction of brain tissue.
b) Intracranial haemorrhage (cerebral, intraventricular or subarachnoid).
The diagnosis must be supported by both of the following:
a) Evidence of permanent neurological deficit with persisting symptoms confirmed by a specialist physician as a definite result of the stroke at least six weeks after the event.
b) Findings on MRI, CT, or other reliable imaging evidence consistent with the diagnosis of a new stroke.
The following are not covered:
- Transient ischaemic attacks.
- Brain damage due to an accident, injury, infection, or non-vasculitic inflammatory disease.
- Vascular disease affecting the eye or optic nerve.
- Ischaemic disorders of the vestibular system.
- Strokes caused by or related to illicit drug use or substance abuse.
- Migraine.
- Hypoxic events.
Words within the definition that have special meaning
“Permanent neurological deficit with persisting symptoms” means dysfunction in the nervous system that is present on clinical examination and expected to last throughout the insured person's life. It includes outcomes such as: numbness, hypertonicity, hemiplegia, monoplegia, hemiparesis, monoparesis, hyperaesthesia (increased sensitivity), paralysis, localised weakness, dysarthria (difficulty with speech), aphasia (inability to speak), dysphagia (difficulty in swallowing), visual impairment, difficulty in walking, lack of coordination, tremor, coma and objectively documented significant loss of cognitive function.
The following do not constitute “permanent neurological deficit with persisting symptoms”:
- An abnormality seen on brain or other scans without definite related clinical symptoms.
- Neurological signs occurring without symptomatic abnormality, such as brisk reflexes without other symptoms.
- Symptoms of psychological or psychiatric origin.
|
ANZ Recover Well dated 1 June 2019
|
The following information is to be read in conjunction with the ‘Critical Illness Cover’ section on page 15 of the PDS.
Life Insurance Code of Practice
We have adopted the Life Insurance Code of Practice, which contains minimum standard medical definitions for certain conditions. This means that where your critical illness cover includes one of the conditions defined under the Code and you make a claim, we will assess your claim against the better of the following definitions:
a) the applicable definition in the PDS for the covered condition
b) if different from a) above, the corresponding minimum standard medical definition in the Code that is current at the time of the insured event.
The minimum standard medical definitions provided under the Code only apply to critical illness cover where we issued your policy on or after 1 July 2017. They do not apply to any of the following:
a) other benefits such as critical illness cover either reinstated after a claim or where the amount payable varies according to the severity of the condition
b) to payments for benefits included with Income Protection or Total and Permanent Disability (TPD).
The minimum standard medical definitions provided under the Code are:
a) Cancer – excluding specified early-stage cancers
Cancer means any malignant tumour diagnosed with histological confirmation and characterised by:
a) the uncontrolled growth of malignant cells; and
b) invasion and destruction of normal tissue beyond the basement membrane.
The term malignant tumour includes leukaemia, sarcoma and lymphoma.
The following are not covered:
- All tumours which are histologically classified as any of the following:
a) pre-malignant;
b) non-invasive;
c) high-grade dysplasia;
d) borderline or low malignant potential.
- Carcinoma in situ except carcinoma in situ of the breast where a total mastectomy with full removal of the breast has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the prostate unless:
a) histologically classified as having a Gleason score of 7 or above; or
b) having progressed to at least clinical stage T2bN0M0 on the TNM clinical staging system; or
c) where a total prostatectomy has been undertaken where the procedure was specifically to arrest the spread of malignancy and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the thyroid unless:
a) having progressed to at least TNM classification T2N0M0; or
b) where a total thyroidectomy has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the bladder unless having progressed to at least TNM classification T1N0M0.
- Cutaneous lymphoma confined to the skin.
- Chronic lymphocytic leukaemia unless having progressed to at least Rai stage I.
- All non-melanoma skin cancers unless having spread to the bone, lymph node, or another distant organ.
- All melanoma skin cancers unless having progressed to at least TNM classification T2bN0M0.
b) Heart attack – with evidence of severe heart muscle damage
Heart attack means the death of a portion of the heart muscle as a result of inadequate blood supply, where the diagnosis is supported by the detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) and with at least three of the following:
a) Symptoms of ischaemia.
b) New significant ST-segment–T wave (ST–T) ECG changes or new left bundle branch block (LBBB).
c) Development of new pathological Q waves in the ECG.
d) Imaging evidence of new regional wall motion abnormality present at least six weeks after the event. If the tests specified in a) to d) above are inconclusive or unable to be met, then the definition will be met if at least three months after the event the insured's left ventricular ejection fraction is less than 50 per cent.
The following are not covered:
- A rise in biological markers as a result of an elective percutaneous procedure for coronary artery disease.
- Other acute coronary syndromes including but not limited to angina pectoris.
c) Stroke – in the brain resulting in specified permanent impairment
Stroke means death of brain tissue caused by one of the following:
a) Ischaemic infarction of brain tissue.
b) Intracranial haemorrhage (cerebral, intraventricular or subarachnoid).
The diagnosis must be supported by both of the following:
a) Evidence of permanent neurological deficit with persisting symptoms confirmed by a specialist physician as a definite result of the stroke at least six weeks after the event.
b) Findings on MRI, CT, or other reliable imaging evidence consistent with the diagnosis of a new stroke.
The following are not covered:
- Transient ischaemic attacks.
- Brain damage due to an accident, injury, infection, or non-vasculitic inflammatory disease.
- Vascular disease affecting the eye or optic nerve.
- Ischaemic disorders of the vestibular system.
- Strokes caused by or related to illicit drug use or substance abuse.
- Migraine.
- Hypoxic events.
Words within the definition that have special meaning
“Permanent neurological deficit with persisting symptoms” means dysfunction in the nervous system that is present on clinical examination and expected to last throughout the insured person's life. It includes outcomes such as: numbness, hypertonicity, hemiplegia, monoplegia, hemiparesis, monoparesis, hyperaesthesia (increased sensitivity), paralysis, localised weakness, dysarthria (difficulty with speech), aphasia (inability to speak), dysphagia (difficulty in swallowing), visual impairment, difficulty in walking, lack of coordination, tremor, coma and objectively documented significant loss of cognitive function.
The following do not constitute “permanent neurological deficit with persisting symptoms”:
- An abnormality seen on brain or other scans without definite related clinical symptoms.
- Neurological signs occurring without symptomatic abnormality, such as brisk reflexes without other symptoms.
- Symptoms of psychological or psychiatric origin.
|
ANZ Income Protection
21 May 2016
|
The government has updated the 457 visa to a “Temporary Skills Shortage” visa.
YOU NEED TO MEET CERTAIN CRITERIA TO APPLY FOR THIS INSURANCE
You must meet all the following criteria to be eligible to apply for cover.
Age: You must be between 18 and 59 years old (inclusive).
Residency: You must currently be living in and receiving this PDS in Australia, and either:
- an Australian or New Zealand Citizen
- an Australian Permanent Resident, or
- a holder of a valid Temporary Skills Shortage or Temporary Work (Skilled) (subclass 457) visa.
Current employment: You must be currently employed more than 20 hours a week in your main occupation.
Previous work history: Unless you hold a valid Temporary Skills Shortage or Temporary Work (Skilled) (subclass 457) visa, you must either:
- have been employed or self-employed continuously for 12 months in Australia or New Zealand in the 24 months before your application for cover, or
- be a recent graduate, meaning you’ve graduated in the last 12 months with a University or Vocational Education and Training (VET) qualification in Australia or New Zealand and are currently employed (but not self-employed).
|
ANZ Life Insurance Product Disclosure Statement and Policy – dated 21 May 2016
|
The following updates the text on the inside of the back cover (updated words in bold). This is to reflect the replacement of the Grow app with the new ANZ App.
Download the ANZ App from the App Store
The ANZ App is provided by Australia and New Zealand Banking Group Limited (ANZ) ABN 11 005 357 522. ANZ recommends that you read the ANZ App Terms and Conditions available at www.anz.com and consider if this service is appropriate to you prior to making a decision to acquire or use the ANZ App.
App Store is a service mark of Apple Inc.
|
ANZ Recover Well Product Disclosure Statement and Policy – dated 21 May 2016
|
The following updates the text on the inside of the back cover (updated words in bold). This is to reflect the replacement of the Grow app with the new ANZ App.
Download the ANZ App from the App Store
The ANZ App is provided by Australia and New Zealand Banking Group Limited (ANZ) ABN 11 005 357 522. ANZ recommends that you read the ANZ App Terms and Conditions available at www.anz.com and consider if this service is appropriate to you prior to making a decision to acquire or use the ANZ App.
App Store is a service mark of Apple Inc.
|
ANZ Income Protection Product Disclosure Statement and Policy – dated 21 May 2016
|
The following updates the text on the inside of the back cover (updated words in bold). This is to reflect the replacement of the Grow app with the new ANZ App.
Download the ANZ App from the App Store
The ANZ App is provided by Australia and New Zealand Banking Group Limited (ANZ) ABN 11 005 357 522. ANZ recommends that you read the ANZ App Terms and Conditions available at www.anz.com and consider if this service is appropriate to you prior to making a decision to acquire or use the ANZ App.
App Store is a service mark of Apple Inc.
|
ANZ Travel Insurance dated 29 February 2016
|
Effective from: 1 December 2017
The Product Disclosure Statement is updated by replacing the phone number for the Financial Ombudsman Service (FOS) on page 52 with 1800 367 287.
|
ANZ 50+ Life Cover Product Disclosure Statement and Policy – dated 28 April 2011
|
The following update extends the current cooling-off period from 21 days to 30 days (updated words in bold)
Cooling-off period (Page 9 of the ANZ 50+ Life Cover PDS)
You may cancel your policy at any time.
If you cancel your policy within 30 days of receiving the Policy Schedule and no claims have been made under the policy, we will refund any premiums paid.
After the cooling-off period, we will not refund any monthly or fortnightly premiums if the policy is cancelled. We will pay a pro rata refund where premiums are paid annually and you cancel the policy before the next annual payment is due.
You can cancel the policy within 30 days of receiving the Policy Schedule by contacting us on 13 16 14.
|
ANZ Accident Cover Plus Product Disclosure Statement and Policy - dated 20 March 2012
|
The following update extends the current cooling-off period from 21 days to 30 days (updated words in bold)
Cooling-off period and cancellation (Page 12 of the ANZ Accident Cover Plus PDS)
You may cancel your policy at any time.
If the policy is cancelled or avoided during the 30 day cooling-off period, we will return any premiums paid, provided no claim has been made. After the cooling off period, we will not refund any monthly or fortnightly premiums if the policy is cancelled. We will pay a pro rata refund where premiums are paid annually and you cancel the policy before the next annual payment is due.
You can cancel the policy within 30 days of receiving the Policy Schedule by contacting us on 13 16 14.
|
OneCare and OneCare Super dated 6 November 2016
|
The following information will be included on page 2 of the PDS and Policy Terms.
Life Insurance Code of Practice
We have adopted the Life Insurance Code of Practice (‘Code’), which contains minimum standard medical definitions for certain conditions. This means that where your Trauma Comprehensive and Premier Covers includes one of the conditions defined under the Code and you make a claim, we will assess your claim against the better of the following definitions:
a) the applicable definition in our PDS linked to the full benefit amount
b) if different from a) above, the corresponding minimum standard medical definition in the Code that is current at the time of the insured event.
The minimum standard medical definitions provided under the Code only apply to Trauma Comprehensive and Premier Covers where we issued your policy on or after 1 July 2017. They do not apply to any of the following:
a) other benefits such as Trauma Cover either reinstated after a claim or where the amount payable varies according to the severity of the condition
b) to payments for benefits included with Income Secure or Total and Permanent Disability (TPD) Cover.
The minimum standard medical definitions provided under the Code are:
a) Cancer – excluding specified early-stage cancers
Cancer means any malignant tumour diagnosed with histological confirmation and characterised by:
a) the uncontrolled growth of malignant cells; and
b) invasion and destruction of normal tissue beyond the basement membrane.
The term malignant tumour includes leukaemia, sarcoma and lymphoma.
The following are not covered:
- All tumours which are histologically classified as any of the following:
a) pre-malignant;
b) non-invasive;
c) high-grade dysplasia;
d) borderline or low malignant potential.
- Carcinoma in situ except carcinoma in situ of the breast where a total mastectomy with full removal of the breast has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the prostate unless:
a) histologically classified as having a Gleason score of 7 or above; or
b) having progressed to at least clinical stage T2bN0M0 on the TNM clinical staging system; or
c) where a total prostatectomy has been undertaken where the procedure was specifically to arrest the spread of malignancy and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the thyroid unless:
a) having progressed to at least TNM classification T2N0M0; or
b) where a total thyroidectomy has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the bladder unless having progressed to at least TNM classification T1N0M0.
- Cutaneous lymphoma confined to the skin.
- Chronic lymphocytic leukaemia unless having progressed to at least Rai stage I.
- All non-melanoma skin cancers unless having spread to the bone, lymph node, or another distant organ.
- All melanoma skin cancers unless having progressed to at least TNM classification T2bN0M0.
b) Heart attack – with evidence of severe heart muscle damage
Heart attack means the death of a portion of the heart muscle as a result of inadequate blood supply, where the diagnosis is supported by the detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) and with at least three of the following:
a) Symptoms of ischaemia.
b) New significant ST-segment–T wave (ST–T) ECG changes or new left bundle branch block (LBBB).
c) Development of new pathological Q waves in the ECG.
d) Imaging evidence of new regional wall motion abnormality present at least six weeks after the event.
If the tests specified in a) to d) above are inconclusive or unable to be met, then the definition will be met if at least three months after the event the insured's left ventricular ejection fraction is less than 50 per cent.
The following are not covered:
- A rise in biological markers as a result of an elective percutaneous procedure for coronary artery disease.
- Other acute coronary syndromes including but not limited to angina pectoris.
c) Stroke – in the brain resulting in specified permanent impairment
Stroke means death of brain tissue caused by one of the following:
a) Ischaemic infarction of brain tissue.
b) Intracranial haemorrhage (cerebral, intraventricular or subarachnoid).
The diagnosis must be supported by both of the following:
a) Evidence of permanent neurological deficit with persisting symptoms confirmed by a specialist physician as a definite result of the stroke at least six weeks after the event.
b) Findings on MRI, CT, or other reliable imaging evidence consistent with the diagnosis of a new stroke.
The following are not covered:
- Transient ischaemic attacks.
- Brain damage due to an accident, injury, infection, or non-vasculitic inflammatory disease.
- Vascular disease affecting the eye or optic nerve.
- Ischaemic disorders of the vestibular system.
- Strokes caused by or related to illicit drug use or substance abuse.
- Migraine.
- Hypoxic events.
Words within the definition that have special meaning
“Permanent neurological deficit with persisting symptoms” means dysfunction in the nervous system that is present on clinical examination and expected to last throughout the insured person's life. It includes outcomes such as: numbness, hypertonicity, hemiplegia, monoplegia, hemiparesis, monoparesis, hyperaesthesia (increased sensitivity), paralysis, localised weakness, dysarthria (difficulty with speech), aphasia (inability to speak), dysphagia (difficulty in swallowing), visual impairment, difficulty in walking, lack of coordination, tremor, coma and objectively documented significant loss of cognitive function.
The following do not constitute “permanent neurological deficit with persisting symptoms”:
- An abnormality seen on brain or other scans without definite related clinical symptoms.
- Neurological signs occurring without symptomatic abnormality, such as brisk reflexes without other symptoms.
- Symptoms of psychological or psychiatric origin.
|
ANZ Recover Well dated 21 May 2016
|
The following information is to be read in conjunction with the ‘Critical Illness Cover’ section on page 13 of the PDS.
Life Insurance Code of Practice
We have adopted the Life Insurance Code of Practice, which contains minimum standard medical definitions for certain conditions. This means that where your critical illness cover includes one of the conditions defined under the Code and you make a claim, we will assess your claim against the better of the following definitions:
a) the applicable definition in the PDS for the covered condition
b) if different from a) above, the corresponding minimum standard medical definition in the Code that is current at the time of the insured event.
The minimum standard medical definitions provided under the Code only apply to critical illness cover where we issued your policy on or after 1 July 2017. They do not apply to any of the following:
a) other benefits such as critical illness cover either reinstated after a claim or where the amount payable varies according to the severity of the condition
b) to payments for benefits included with Income Protection or Total and Permanent Disability (TPD).
The minimum standard medical definitions provided under the Code are:
a) Cancer – excluding specified early-stage cancers
Cancer means any malignant tumour diagnosed with histological confirmation and characterised by:
a) the uncontrolled growth of malignant cells; and
b) invasion and destruction of normal tissue beyond the basement membrane.
The term malignant tumour includes leukaemia, sarcoma and lymphoma.
The following are not covered:
- All tumours which are histologically classified as any of the following:
a) pre-malignant;
b) non-invasive;
c) high-grade dysplasia;
d) borderline or low malignant potential.
- Carcinoma in situ except carcinoma in situ of the breast where a total mastectomy with full removal of the breast has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the prostate unless:
a) histologically classified as having a Gleason score of 7 or above; or
b) having progressed to at least clinical stage T2bN0M0 on the TNM clinical staging system; or
c) where a total prostatectomy has been undertaken where the procedure was specifically to arrest the spread of malignancy and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the thyroid unless:
a) having progressed to at least TNM classification T2N0M0; or
b) where a total thyroidectomy has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the bladder unless having progressed to at least TNM classification T1N0M0.
- Cutaneous lymphoma confined to the skin.
- Chronic lymphocytic leukaemia unless having progressed to at least Rai stage I.
- All non-melanoma skin cancers unless having spread to the bone, lymph node, or another distant organ.
- All melanoma skin cancers unless having progressed to at least TNM classification T2bN0M0.
b) Heart attack – with evidence of severe heart muscle damage
Heart attack means the death of a portion of the heart muscle as a result of inadequate blood supply, where the diagnosis is supported by the detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) and with at least three of the following:
a) Symptoms of ischaemia.
b) New significant ST-segment–T wave (ST–T) ECG changes or new left bundle branch block (LBBB).
c) Development of new pathological Q waves in the ECG.
d) Imaging evidence of new regional wall motion abnormality present at least six weeks after the event.
If the tests specified in a) to d) above are inconclusive or unable to be met, then the definition will be met if at least three months after the event the insured's left ventricular ejection fraction is less than 50 per cent.
The following are not covered:
- A rise in biological markers as a result of an elective percutaneous procedure for coronary artery disease.
- Other acute coronary syndromes including but not limited to angina pectoris.
c) Stroke – in the brain resulting in specified permanent impairment
Stroke means death of brain tissue caused by one of the following:
a) Ischaemic infarction of brain tissue.
b) Intracranial haemorrhage (cerebral, intraventricular or subarachnoid).
The diagnosis must be supported by both of the following:
a) Evidence of permanent neurological deficit with persisting symptoms confirmed by a specialist physician as a definite result of the stroke at least six weeks after the event.
b) Findings on MRI, CT, or other reliable imaging evidence consistent with the diagnosis of a new stroke.
The following are not covered:
- Transient ischaemic attacks.
- Brain damage due to an accident, injury, infection, or non-vasculitic inflammatory disease.
- Vascular disease affecting the eye or optic nerve.
- Ischaemic disorders of the vestibular system.
- Strokes caused by or related to illicit drug use or substance abuse.
- Migraine.
- Hypoxic events.
Words within the definition that have special meaning
“Permanent neurological deficit with persisting symptoms” means dysfunction in the nervous system that is present on clinical examination and expected to last throughout the insured person's life. It includes outcomes such as: numbness, hypertonicity, hemiplegia, monoplegia, hemiparesis, monoparesis, hyperaesthesia (increased sensitivity), paralysis, localised weakness, dysarthria (difficulty with speech), aphasia (inability to speak), dysphagia (difficulty in swallowing), visual impairment, difficulty in walking, lack of coordination, tremor, coma and objectively documented significant loss of cognitive function.
The following do not constitute “permanent neurological deficit with persisting symptoms”:
- An abnormality seen on brain or other scans without definite related clinical symptoms.
- Neurological signs occurring without symptomatic abnormality, such as brisk reflexes without other symptoms.
- Symptoms of psychological or psychiatric origin.
|
ANZ Life Insurance dated 21 May 2016
|
The following information is to be read in conjunction with the ‘Critical Illness Cover (optional)’ section on page 14 of the PDS
Life Insurance Code of Practice
We have adopted the Life Insurance Code of Practice, which contains minimum standard medical definitions for certain conditions. This means that where your critical illness cover includes one of the conditions defined under the Code and you make a claim, we will assess your claim against the better of the following definitions:
a) the applicable definition in the PDS for the covered condition
b) if different from a) above, the corresponding minimum standard medical definition in the Code that is current at the time of the insured event.
The minimum standard medical definitions provided under the Code only apply to critical illness cover where we issued your policy on or after 1 July 2017. They do not apply to any of the following:
a) other benefits such as critical illness cover either reinstated after a claim or where the amount payable varies according to the severity of the condition
b) to payments for benefits included with Income Protection or Total and Permanent Disability (TPD).
The minimum standard medical definitions provided under the Code are:
a) Cancer – excluding specified early-stage cancers
Cancer means any malignant tumour diagnosed with histological confirmation and characterised by:
a) the uncontrolled growth of malignant cells; and
b) invasion and destruction of normal tissue beyond the basement membrane.
The term malignant tumour includes leukaemia, sarcoma and lymphoma.
The following are not covered:
- All tumours which are histologically classified as any of the following:
a) pre-malignant;
b) non-invasive;
c) high-grade dysplasia;
d) borderline or low malignant potential.
- Carcinoma in situ except carcinoma in situ of the breast where a total mastectomy with full removal of the breast has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the prostate unless:
a) histologically classified as having a Gleason score of 7 or above; or
b) having progressed to at least clinical stage T2bN0M0 on the TNM clinical staging system; or
c) where a total prostatectomy has been undertaken where the procedure was specifically to arrest the spread of malignancy and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the thyroid unless:
a) having progressed to at least TNM classification T2N0M0; or
b) where a total thyroidectomy has been undertaken and was considered by treating doctors to be the appropriate and necessary treatment.
- All cancers of the bladder unless having progressed to at least TNM classification T1N0M0.
- Cutaneous lymphoma confined to the skin.
- Chronic lymphocytic leukaemia unless having progressed to at least Rai stage I.
- All non-melanoma skin cancers unless having spread to the bone, lymph node, or another distant organ.
- All melanoma skin cancers unless having progressed to at least TNM classification T2bN0M0.
b) Heart attack – with evidence of severe heart muscle damage
Heart attack means the death of a portion of the heart muscle as a result of inadequate blood supply, where the diagnosis is supported by the detection of a rise and/or fall of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) and with at least three of the following:
a) Symptoms of ischaemia.
b) New significant ST-segment–T wave (ST–T) ECG changes or new left bundle branch block (LBBB).
c) Development of new pathological Q waves in the ECG.
d) Imaging evidence of new regional wall motion abnormality present at least six weeks after the event.
If the tests specified in a) to d) above are inconclusive or unable to be met, then the definition will be met if at least three months after the event the insured's left ventricular ejection fraction is less than 50 per cent.
The following are not covered:
- A rise in biological markers as a result of an elective percutaneous procedure for coronary artery disease.
- Other acute coronary syndromes including but not limited to angina pectoris.
c) Stroke – in the brain resulting in specified permanent impairment
Stroke means death of brain tissue caused by one of the following:
a) Ischaemic infarction of brain tissue.
b) Intracranial haemorrhage (cerebral, intraventricular or subarachnoid).
The diagnosis must be supported by both of the following:
a) Evidence of permanent neurological deficit with persisting symptoms confirmed by a specialist physician as a definite result of the stroke at least six weeks after the event.
b) Findings on MRI, CT, or other reliable imaging evidence consistent with the diagnosis of a new stroke.
The following are not covered:
- Transient ischaemic attacks.
- Brain damage due to an accident, injury, infection, or non-vasculitic inflammatory disease.
- Vascular disease affecting the eye or optic nerve.
- Ischaemic disorders of the vestibular system.
- Strokes caused by or related to illicit drug use or substance abuse.
- Migraine.
- Hypoxic events.
Words within the definition that have special meaning
“Permanent neurological deficit with persisting symptoms” means dysfunction in the nervous system that is present on clinical examination and expected to last throughout the insured person's life. It includes outcomes such as: numbness, hypertonicity, hemiplegia, monoplegia, hemiparesis, monoparesis, hyperaesthesia (increased sensitivity), paralysis, localised weakness, dysarthria (difficulty with speech), aphasia (inability to speak), dysphagia (difficulty in swallowing), visual impairment, difficulty in walking, lack of coordination, tremor, coma and objectively documented significant loss of cognitive function.
The following do not constitute “permanent neurological deficit with persisting symptoms”:
- An abnormality seen on brain or other scans without definite related clinical symptoms.
- Neurological signs occurring without symptomatic abnormality, such as brisk reflexes without other symptoms.
- Symptoms of psychological or psychiatric origin.
|
ANZ SecureLife Plan dated 15 November 2010
ANZ BirthdayLife Plan dated 15 November 2010
ANZ Recover Well dated 25 March 2013
|
This applies in relation to the information you may provide when updating your policy.
Duty of Disclosure
Before you enter into a life insurance contract, you have a duty to tell us anything that you know, or could reasonably be expected to know, may affect our decision to insure you and on what terms.
You have this duty until we agree to insure you.
You have the same duty before you extend, vary or reinstate the contract.
You do not need to tell us anything that:
- reduces the risk we insure you for; or
- is common knowledge; or
- we know or should know as an insurer; or
- we waive your duty to tell us about.
If the insurance is for the life of another person and that person does not tell us everything he or she should have, this may be treated as a failure by you to tell us something that you must tell us.
If you do not tell us something
In exercising the following rights, we may consider whether different types of cover can constitute separate contracts of life insurance. If they do, we may apply the following rights separately to each type of cover.
If you do not tell us anything you are required to, and we would not have insured you or entered into the same contract if you had told us, we may avoid the contract within 3 years of entering into it.
If we choose not to avoid the contract, we may, at any time, reduce the amount you have been insured for. This would be worked out using a formula that takes into account the premium that would have been payable if you had told us everything you should have. However, if the contract has a surrender value, or provides cover on death, we may only exercise this right within 3 years of entering into the contract.
If we choose not to avoid the contract or reduce the amount you have been insured for, we may, at any time vary the contract in a way that places us in the same position we would have been in if you had told us everything you should have. However, this right does not apply if the contract provides cover on death.
If your failure to tell us is fraudulent, we may refuse to pay a claim and treat the contract as if it never existed |
EasyProtect Life dated 15 November 2010
EasyProtect Major Illness dated 15 November 2010
EasyProtect Income dated 15 November 2010
ANZ Life Insurance dated 8 November 2010
ANZ Critical Illness Cover dated 8 November 2010
ANZ Income Protection dated 8 November 2010
OnePath SecureLife Plan dated 15 November 2010
ANZ SecureLife Plan dated 15 November 2010
ANZ BirthdayLife Plan dated 15 November 2010
ProSecure Income Replacement Plan dated 15 November 2010
|
The following paragraph is inserted at the end of the "About the premium" section of each of the above product disclosure statements:
You may be entitled to earn Qantas Frequent Flyer points on the premiums you pay for this policy. Please visit our website at onepath.com.au/qff-terms-conditions for details.
|
Home Insurance dated 15 November 2010
Landlord Insurance dated 15 November 2010
Car Insurance dated 15 November 2010
|
The following paragraph is inserted at the end of the "Your premium" section of each of the above product disclosure statements:
|
Travel Insurance dated 15 November 2010
|
The Travel Insurance Product Disclosure Statement dated 15 November 2010 is updated by inserting the following paragraph after the "The cost of this insurance" section on page 43:
|
ANZ Income Protection dated 28 April 2011
EasyProtect Income dated 28 April 2011
|
The Product Disclosure Statement is updated by replacing the fourth paragraph in the "Waiting period" section on page 7 with the following:
If you return to work in your regular occupation or any other gainful occupation during the waiting period for no more than five consecutive days, the days spent at work will be added to the remaining waiting period.
|
Professionals Life Cover Plus
For Medical Professionals
Product Disclosure Statement and Policy (PDS)
Dated 1 August 2011
Professionals Life Cover Plus
Product Disclosure Statement and Policy (PDS)
Dated1 August 2011
|
The following updates enable premiums to be paid in fortnightly instalments (updated words in bold):
‘About the Premium’ section – second paragraph (Page 11 of each PDS):
“Premiums can be paid fortnightly, monthly or annually by direct debit from a credit card or bank account.”
‘Discount for combined cover’ section (Page 12 of each PDS:
“If you take out cover for yourself as the principal life insured and also for a second life insured, the following discounts will apply to the premium in respect of the second life insured:
• if you pay fortnightly, a discount of $2.50 off the fortnightly premium,
• if you pay monthly, a discount of $5 off the monthly premium,
• if you pay annually, a discount of $40 off the annual premium.”
‘Cooling-off period and cancellation’ section – second paragraph (Page 14 of each PDS:
“If the policy is cancelled or avoided during the 21 day cooling-off period, we will return any premiums paid, providing no claim has been made. After the cooling off period, we will not refund any fortnightly or monthly premiums if the policy is cancelled.”
|
Car Insurance dated 15 November 2010
ANZ Car Insurance dated 20 November 2010
Home Insurance dated 15 November 2010
ANZ Home Insurance dated 20 November 2010
Landlord Insurance dated 15 November 2010
ANZ Landlord Insurance dated 20 November 2010
|
The following paragraph is inserted at the end of the "How we calculate your premium" section of the product disclosure statement:
From time to time, the issuers may promote special offers relating to the purchase of this product which may include discounts, cash-back or loyalty incentives. To find out what special offers maybe available to you, visit your local ANZ branch or call 13 16 14 for more information.
|
Travel Insurance dated 15 November 2010
ANZ Travel Insurance dated 20 November 2010
|
The following paragraph is inserted at the end of the "What you have to pay" section of product disclosure statement:
From time to time, the issuers may promote special offers relating to the purchase of this product which may include discounts, cash-back or loyalty incentives. To find out what special offers maybe available to you, visit your local ANZ branch or call 13 16 14 for more information.
|
ANZ Loan Protection dated 28 February 2011
|
The following paragraph is inserted at the end of the "How is the premium calculated?" section the product disclosure statement:
From time to time, the issuers may promote special offers relating to the purchase of this product which may include discounts, cash-back or loyalty incentives. To find out what special offers maybe available to you, visit your local ANZ branch or call 1300 552 253 for more information.
|
ANZ Mortgage Protection dated 28 February 2011
|
The following paragraph is inserted at the end of the "How is the premium calculated?" section the product disclosure statement:
From time to time, the issuers may promote special offers relating to the purchase of this product which may include discounts, cash-back or loyalty incentives. To find out what special offers maybe available to you, visit your local ANZ branch or call 13 33 33 for more information.
|
ANZ Credit Card Insurance dated 1 April 2012
A reminder about your credit card insurance
|
The following paragraph is included as paragraph 4 under the ‘Definition and amount payable’ for the ‘Involuntary Unemployment Benefit’ on page 14 of the ANZ Credit Card Insurance Product Disclosure Statement.
For policyholders holding a Temporary Business (Long Stay) – Standard Business Sponsorship (Subclass 457) Visa, who are not able to meet the requirements detailed in the paragraph above, subject to the application of the waiting period, benefit payments commence from when you provide evidence of your employment termination and evidence to our satisfaction that you are actively seeking employment in your country of residence.
|
ANZ Mortgage Protection Insurance dated 28 February 2011
|
Effective from: 28 June 2014
The Product Disclosure Statement is updated by replacing the "Non-Disclosure – Life Benefit cover" section on page 2 with the following:
Non-Disclosure – Life Benefit cover
If you do not disclose to us every matter that you know or could reasonably be expected to know, that would be relevant to our decision whether to accept the risk of the insurance and if so, on what terms, we may avoid the contract, or avoid your cover within three years of entering into it, provided that we would not have entered into that contract or accepted cover for you had full disclosure been made.
Where we are entitled to avoid a contract of life insurance, we may elect not to avoid it but apply either of the following options:
• reduce the sum that you would have been insured for in accordance with a formula that takes into account the premium that would have been payable if you had disclosed all relevant matters to the insurer; or
• vary the contract in such a way as to place us in a position that we would have been had you disclosed all relevant matters.
Where your contract is in respect of death cover, we may only apply the first of the two options and we must do so within three years of you entering into the contract or us providing cover to you
|
ANZ Loan Protection Insurance dated 28 February 2011
|
Effective from: 28 June 2014
The Product Disclosure Statement is updated by replacing the "Non-Disclosure – Life Benefit cover" section on page 3 with the following:
Non-Disclosure – Life Benefit cover
If you do not disclose to us every matter that you know or could reasonably be expected to know, that would be relevant to our decision whether to accept the risk of the insurance and if so, on what terms, we may avoid the contract, or avoid your cover within three years of entering into it, provided that we would not have entered into that contract or accepted cover for you had full disclosure been made.
Where we are entitled to avoid a contract of life insurance, we may elect not to avoid it but apply either of the following options:
• reduce the sum that you would have been insured for in accordance with a formula that takes into account the premium that would have been payable if you had disclosed all relevant matters to the insurer; or
• vary the contract in such a way as to place us in a position that we would have been had you disclosed all relevant matters.
Where your contract is in respect of death cover, we may only apply the first of the two options and we must do so within three years of you entering into the contract or us providing cover to you.
|
QBE Lease Protection Insurance dated June 2011
|
Effective from: 28 June 2014
The Product Disclosure Statement is updated by removing the second and third paragraph in the "If you do not tell us" section of page 4.
|
ANZ Credit Card Insurance dated 1 April 2012
|
Effective from 27 February 2016
Click here to view the changes to the Product Disclosure Statement and Policy Document, which includes changes to benefits.
|
ANZ CreditCover Plus dated 28 February 2011
|
Effective from 27 February 2016
Click here to view the changes to the Product Disclosure Statement and Policy Document, which includes changes to benefits.
|
